AE Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q3
Sell
-600
Closed -$1K 631
2018
Q2
$1K Buy
+600
New +$55.1K ﹤0.01% 454

Other funds holding XBI

AE Wealth Management's XBI Position: Q1 2026 in Review

AE Wealth Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 8.1% in Q1 2026, selling an estimated $223K and leaving 20,287 shares worth $2.59M. The position accounts for 0.01% of the portfolio, ranked #573.

AE Wealth Management first reported a position in XBI in Q2 2017 and has held it in 35 quarters since. The position peaked at $5.55M in Q4 2022. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • AE Wealth Management held 20,287 shares of State Street SPDR S&P Biotech ETF worth $2.59M as of Q1 2026.
  • AE Wealth Management sold 1,790 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $223K.
  • State Street SPDR S&P Biotech ETF made up 0.01% of AE Wealth Management's portfolio in Q1 2026, its #573 holding.
  • AE Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2017 and has held it in 35 quarters since.
  • AE Wealth Management's State Street SPDR S&P Biotech ETF position peaked at $5.55M in Q4 2022.
  • 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on AE Wealth Management's 13F filing for Q1 2026, filed 13 May 2026.